Submission of Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-10.1%1-day move

₹60.37

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————-10.1-3.9-3.1-4.1-10.6-8.7-10.6-7.9+26.9+10.1

Up moveDown movePending

AI summary

Novelix Pharmaceuticals has submitted a compliance certificate from its Registrar and Share Transfer Agent, Venture Capital and Corporate Investments Private Limited, confirming adherence to SEBI dematerialization norms. The certificate verifies that securities received for dematerialization were properly mutilated and cancelled after verification, with NSDL and CDSL updated as registered owners within the 15-day statutory timeframe. The filing covers the quarter ending 31st March, 2026. This is a routine regulatory compliance submission required under SEBI regulations for all listed companies. The Whole-time Director Venkateshwarlu Pulluru signed the submission dated 9th April, 2026.

Likely market impact

This is a procedural regulatory filing with no direct impact on the company's financial position or stock price. It simply confirms that the company followed proper dematerialization procedures for share certificates during the quarter. Shareholders can note this as routine compliance documentation.